Immunovant COO sells 3,056 shares for tax withholding
Immunovant, Inc. (IMVT) reported that Chief Operating Officer Gloria Melanie sold 3,056 shares of common stock on August 20, 2026, at a weighted average price of $44.16 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Immunovant, Inc. (IMVT) reported that Chief Operating Officer Gloria Melanie sold 3,056 shares of common stock on August 20, 2026, at a weighted average price of $44.16 per share. The shares were sold to cover tax withholding obligations arising from the vesting and settlement of previously granted RSUs under a mandated “sell to cover” arrangement, and are described as not being a discretionary transaction by the officer. Following this sale, she holds 219,301 shares of Immunovant common stock directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 3,056 | $44.16 | $135K |
Footnotes (2)
- F1. On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on August 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.80 - $44.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Key Figures
Key Terms
restricted stock units ("RSUs") financial
sell to cover financial
weighted average price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Immunovant (IMVT) disclose for Gloria Melanie?
What equity awards underpin the reported Immunovant (IMVT) tax-withholding sale?
Was the Immunovant (IMVT) Form 4 sale under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.